Advertisement

Topics

I/O combos inch forward in pharma's lung cancer quest

05:30 EDT 16 Apr 2018 | BioPharmaDive

An impressive survival benefit could lift Merck's Keytruda plus chemo regimen, while Bristol-Myers hopes its checkpoint inhibitor pairing can help it catch up. 

Original Article: I/O combos inch forward in pharma's lung cancer quest

NEXT ARTICLE

More From BioPortfolio on "I/O combos inch forward in pharma's lung cancer quest"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...